Overview of Teva-Trazodone

Property	Description
Active ingredient	Trazodone Hydrochloride
Form	Oral tablet, Extended-release oral tablet
Pharmacological class	Atypical Antidepressant
Common use	Treatment of Major Depressive Disorder (MDD)
Origin	Synthetic triazolopyridine derivative

What Type of Medication is Teva-Trazodone?

Teva-Trazodone is a widely distributed, prescription-only generic medication defined by the active ingredient Trazodone Hydrochloride, which is chemically classified as a triazolopyridine derivative. This medication belongs to the pharmacological class of Serotonin Receptor Antagonists and Reuptake Inhibitors (SARI), a grouping that reflects its dual function within the central nervous system. As a SARI, Trazodone is structurally distinct from other major antidepressant groups, such as the Selective Serotonin Reuptake Inhibitors (SSRIs). Trazodone has demonstrated antidepressant activity comparable to that of other established drug classes. This comparison underscores the medication's clinically recognized effectiveness in managing symptoms of depression.

What Is the Purpose and General Function of Trazodone?

The general purpose of Trazodone is to help stabilize mood and relieve emotional distress by functioning as a serotonin modulator in the brain. Its primary physiological effect is to alter the activity of neurotransmitters by blocking the 5-HT2A receptor and inhibiting the reuptake of serotonin. This combined approach makes it effective for improving overall emotional state and managing core symptoms of mood imbalance, such as profound emotional disturbances often seen in adult patients. Furthermore, Trazodone is also recognized for its sedative effect, attributed to its antagonistic actions on the histamine and alpha-adrenergic receptors. This property helps relieve sleep-related distress associated with mood disorders, an effect that is often leveraged in therapeutic practice.

Trazodone: Available Forms and Composition

Teva-Trazodone is manufactured as a single active ingredient product for the oral route of administration, utilizing Trazodone Hydrochloride combined with solid pharmaceutical excipients. The medication is commonly available in two primary dosage form(s): the standard oral tablet and the extended-release oral tablet. While both forms contain the same active compound, the extended-release tablet is specifically designed for a different pharmacokinetic profile, aiming to provide a prolonged, consistent effect over a longer period, a differentiating feature crucial for patient adherence and symptom control.

Regulatory References

Trazodone - StatPearls - NCBI Bookshelf

What side effects are possible with Teva-Trazodone?

Possible side effects and safety information

The safety profile for Teva-Trazodone (Trazodone Hydrochloride) is defined by categories established in official regulatory documents, grouping potential effects by frequency and the body system affected, such as Nervous System Disorders and Gastrointestinal Disorders.

Adverse reactions classified as Very Common often include central nervous system effects like drowsiness (somnolence), dizziness, headache, and fatigue, along with common gastrointestinal effects such as dry mouth and nausea. Effects are often more noticeable during the initial phase of treatment or following a dose change.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling documents several serious adverse reactions. These include the risk of Suicidal Thoughts and Behaviors, particularly in children, adolescents, and young adults (up to age 24), which is highlighted via a Boxed Warning. Other high-risk events include Serotonin Syndrome, Cardiac Arrhythmias (including QTc prolongation), and a painful, prolonged erection known as Priapism, which requires immediate intervention. The risk of sudden drops in blood pressure upon standing, or Orthostatic Hypotension which may lead to syncope, is also documented, and is noted as potentially increased in older adults.

Use is formally restricted in patients taking or who have recently stopped taking a Monoamine Oxidase Inhibitor (MAOI), due to the risk of Serotonin Syndrome. Caution is also advised in patients with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory information on Trazodone Hydrochloride overdose emphasizes that symptoms often involve the Central Nervous System and cardiovascular function. Documented manifestations may include somnolence, dizziness, nausea, vomiting, hypotension (low blood pressure), and tachycardia (increased heart rate).

Severe overdose, particularly when taken with alcohol or other CNS depressants, can lead to life-threatening outcomes. These severe outcomes include coma, seizures, respiratory arrest, and critical cardiac arrhythmias such as QT prolongation and Torsade de Pointes.

Immediate medical help is required for any suspected overdose. The official instruction is to seek medical help right away and to contact a Poison Control Center for guidance. Given the cardiovascular risks, continuous cardiac monitoring is mandated in the overdose context. Furthermore, immediate medical attention is necessary if priapism (a prolonged erection) occurs, as this is a severe documented risk.

Management is symptomatic and supportive, as no specific antidote is known. Procedures such as gastric lavage or activated charcoal may be considered depending on the time of ingestion.

Therapeutic Uses of Teva-Trazodone

Trazodone is commonly used to help with symptoms related to depression, addressing conditions like Major Depressive Disorder (MDD). The medication is also relevant for easing anxiety and managing insomnia. This makes it relevant in scenarios where patients experience mood disturbances concurrently with significant sleep problems.

The primary therapeutic focus is managing symptoms related to systemic imbalance, such as profound emotional disturbances and persistent low mood. It generally provides supportive relief that may assist patients in coping more steadily with difficult episodes. Furthermore, Trazodone is commonly applied to address symptoms that interfere with daily functioning, particularly those linked to sleep, such as difficulty falling asleep and frequent nighttime awakenings. The medication also offers symptomatic assistance in managing episodes of psychomotor agitation and irritability.

Use Classification: Support for Sleep and Mood Symptoms

The medication is considered relevant for patients whose depressive symptoms are complicated by symptoms that become more disruptive during flare-ups, such as persistent insomnia, offering symptomatic assistance in assisting with maintaining functional stability.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Teva-Trazodone (Trazodone Hydrochloride) is officially indicated for the treatment of Major Depressive Disorder (MDD) in adults (age 18 and older). Official regulatory labeling strictly defines the populations who may use the medicine and those who are formally excluded.

Absolute Contraindications

Use is prohibited (contraindicated) for individuals with a known hypersensitivity to Trazodone Hydrochloride or any component of the formulation. It must also not be used by patients taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing an MAOI. The medication is not recommended for use during the initial recovery phase following a myocardial infarction.

Age and Condition Restrictions

Pediatric Use: Trazodone is not approved for use in children and adolescents under 18 years of age, as safety and efficacy have not been established in this population.
Geriatric Use: Older adults require caution and close monitoring due to an increased risk of specific events, such as hyponatremia.
Organ and Cardiac Status: Caution is mandatory for patients with pre-existing cardiac disease or severe hepatic (liver) or renal (kidney) impairment.

Reproductive Status

Use during pregnancy is a matter of caution, with some animal data suggesting potential fetal harm. Trazodone is excreted in human milk, and a decision to continue use during lactation must be made with caution, weighing the potential benefits against risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Trazodone Hydrochloride based on its metabolic pathways and its pharmacodynamic effects.

Formal Contraindicated Combinations

The co-administration of Trazodone and Monoamine Oxidase Inhibitors (MAOIs) is explicitly prohibited. A mandatory 14-day washout period is required upon switching between Trazodone and an MAOI. Additionally, the drug is contraindicated in patients taking medicinal products known to prolong the QT interval, such as Pimozide, due to the risk of cardiac arrhythmia. Use is also contraindicated in states of acute intoxication with alcohol or hypnotics.

Clinically Significant Interactions

Interaction Type	Interacting Substances/Classes	Regulatory Outcome
Pharmacokinetic (CYP3A4)	Potent CYP3A4 Inhibitors (e.g., Ritonavir)	Substantial increase in Trazodone plasma concentration (exposure).
Pharmacokinetic (CYP3A4)	Potent CYP3A4 Inducers (e.g., Carbamazepine)	Significant reduction in Trazodone plasma concentration (exposure).
Pharmacodynamic (Serotonin)	Other Serotonergic Drugs (e.g., SSRIs, Triptans)	Increased risk of Serotonin Syndrome.
Pharmacodynamic (CNS)	CNS Depressants and Alcohol	Intensified sedative effects and increased cognitive impairment risk.

Co-administration with NSAIDs and Anticoagulants is noted to increase the risk of Abnormal Bleeding. Caution is advised for Elderly Patients due to a heightened risk of interaction-related effects like Orthostatic Hypotension.

Mechanism of Action

Teva-Trazodone is primarily classified as a Serotonin Receptor Antagonist and Reuptake Inhibitor (SARI), operating through a dual-mechanism on the serotonergic system. It leads to its primary, adaptive physiological consequence by blocking (antagonism) of the mathbf5 -HT2 A receptor and, to a lesser extent, inhibiting the Serotonin Transporter (SERT). This action suppresses specific signaling pathways while concurrently adjusting the availability of serotonin in the synaptic cleft, contributing to neurotransmitter regulation in the Central Nervous System (CNS) over time. The immediate physiological consequence of Trazodone is driven by its interaction with two non-serotonergic targets: the Histamine mathbfH1 receptor and the mathbfalpha1 -Adrenergic receptor. Antagonism at these sites quickly interrupts the signaling pathways that promote wakefulness and sympathetic nervous system outflow. This combined blockade results in a rapid dampening of central nervous system arousal, leading to the physiological consequence of decreased CNS arousal and altered sleep architecture. Additionally, Trazodone is metabolized into the active compound m -Chlorophenylpiperazine (m -CPP), which is itself pharmacologically active at multiple serotonin receptor sites and further modulates the 5 -HT pathways.

Dosage and Administration Information

How to Use Teva-Trazodone: Official Administration Guidelines

Administration of Trazodone Hydrochloride is strictly via the oral route, typically utilizing either the immediate-release (IR) tablet or, where available, the extended-release (ER) formulation. The official use protocol is defined by the formulation-specific requirements for dosing frequency and timing in relation to food intake.

Treatment always begins with a low dose, such as 150 mg per day for IR tablets, administered in divided doses. The dosage is then subject to a scheduled titration, meaning the amount may be increased by 50 mg increments every three to four days, based on the documented protocol. The maximum daily dose for most outpatients using the IR tablet is 400 mg, while for severely depressed inpatients, the dose may be increased up to 600 mg.

Feature	Guideline (Strictly Label-Based)
IR Tablet Timing	Should be taken shortly after a meal or light snack.
ER Tablet Timing	Should be taken once daily (at bedtime) on an empty stomach.
Tablet Handling	IR tablets can be broken along the score line; ER tablets must not be crushed or chewed.

The medication is not approved for use in pediatric patients as safety and efficacy have not been established. For adult maintenance treatment, the drug is typically continued for several months at the lowest effective dose. When therapy is concluded, the official use principle mandates a gradual dose reduction (tapering) rather than abrupt cessation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Research has examined whether the drug may be associated with changes in pain and function in participants with osteoarthritis.

One pivotal Phase III trial reported a change in joint pain scores over 12 weeks that was observed when compared to placebo.

Pain Score Analysis: Investigators recorded a mean change in the Visual Analog Scale (VAS) for pain. The primary endpoint was whether a statistically significant difference in pain was present at Week 12.
Function Assessment: The trial evaluated whether the drug was associated with changes in participants’ scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale.

Quality of Life and Mobility

Studies have explored whether the drug is associated with changes in quality of life by examining mobility.

Reported Outcomes: Participants in the study recorded their quality of life, which was measured using a standardized questionnaire.
Mobility Metrics: The six-minute walk test was used to assess physical performance in the study population.

Combination Therapy Studies

Another study investigated whether combining the drug with standard physical therapy was associated with differences in outcomes.

Study Design: This was an open-label trial that examined participants receiving the combination therapy compared to those receiving physical therapy alone.
Observed Results: The trial reported that participants in the combination group had different average scores across several key measures compared to the monotherapy group.

Safety and Tolerability Profile

Research evaluated the tolerability of long-term use, and investigators recorded the incidence of side effects.

Common Adverse Events: The most frequently reported events included headache and temporary gastrointestinal discomfort.
Specific Populations: One study examined the use of the drug in participants with severe liver impairment.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Teva-Trazodone (FAQ)

Q: Can Teva-Trazodone cause next-day drowsiness or a 'groggy' feeling?

Drowsiness, dizziness, and fatigue are listed in official product information as Very Common side effects, particularly when starting treatment. Because the medication can impair physical and mental abilities, regulatory warnings describe the need for caution regarding activities requiring alertness due to the potential for residual effects, which may persist the day after administration.

Q: What are the signs of a serious or uncommon side effect of Teva-Trazodone that require immediate attention?

Serious reactions are documented in regulatory sources and should prompt contact with a healthcare professional. These include signs of Priapism (a painful, prolonged erection), symptoms consistent with Serotonin Syndrome (such as high fever, agitation, or confusion), seizure activity, or symptoms related to cardiac arrhythmia.

Q: What are the potential effects of stopping Teva-Trazodone suddenly?

The official protocol states that abruptly stopping the medication is generally not recommended. Abrupt cessation may lead to signs consistent with a discontinuation reaction, which has been reported to include dysphoria, agitation, sensory disturbances, or the return of the original condition. Guidance on dose reduction is provided by a healthcare professional.

Q: Are there specific types of food or drinks that should be avoided while taking Teva-Trazodone?

Official warnings state that the use of alcohol is contraindicated due to the risk of intensified sedative effects. Furthermore, the extended-release tablet is officially advised to be taken on an empty stomach for proper absorption, while the immediate-release tablet should be taken shortly after a light snack or meal.

Q: What is Serotonin Syndrome and what is the risk of it occurring with Teva-Trazodone?

Serotonin Syndrome is a serious adverse reaction defined by regulatory agencies by a collection of symptoms. These symptoms may include changes in mental status (such as confusion or agitation), rapid heart rate, fever, and severe muscle rigidity. The risk is increased when Teva-Trazodone is used with other drugs that increase serotonin, though official information indicates it can potentially occur when the drug is used alone.

Q: Can Teva-Trazodone cause confusion or problems with concentration?

Clinical reports have noted confusion and decreased concentration as less common side effects. Regulatory documents indicate the drug has the potential to impair judgment and thinking, which is generally reported to be more pronounced at the beginning of treatment.

Q: Does Teva-Trazodone interact with herbal supplements like St. John's wort or melatonin?

Regulatory cautions apply to any product that increases serotonin levels, such as the herbal supplement St. John’s wort, due to the heightened risk of Serotonin Syndrome. Interaction information regarding other supplements, including melatonin, is not specifically listed in all official regulatory documents.

Q: Can I drive or operate machinery while taking Teva-Trazodone?

The regulatory label contains warnings regarding the need for caution when performing hazardous tasks, such as driving a car or operating heavy machinery. This is due to the drug's documented potential to cause drowsiness, dizziness, and impaired judgment, especially before a patient is aware of how the medication affects them.

Q: How quickly does Teva-Trazodone usually start working for sleep problems?

The onset of the sedating effects has been reported to occur relatively quickly, with physiological changes that aid sleep typically beginning within 30 to 60 minutes after administration. However, this timing can be influenced by factors such as whether the dose is taken with food, as specified in the official use guidelines.

Q: How long does it typically take to feel the full effects of Teva-Trazodone for mood conditions?

The time required to observe the full effects of Trazodone for mood conditions is comparable to that of other medications in its class. While improvement in depressive symptoms may begin within one to two weeks, official sources indicate the full therapeutic benefit may require four to six weeks of consistent treatment.

Q: Does Teva-Trazodone cause changes in appetite or weight?

Changes in appetite and weight are not reported as very common adverse reactions. Official clinical data notes that a small percentage of patients have experienced either a gain or loss of weight during the course of treatment.

Q: Is there a risk of developing dependence on Teva-Trazodone?

Official documents indicate Trazodone is generally not associated with high abuse potential. However, the need to follow the gradual tapering instructions is based on the risk of experiencing withdrawal-like symptoms if the medication is stopped suddenly.

Q: What are the reported effects of Teva-Trazodone on sexual function?

The most serious, though rare, sexual side effect reported in regulatory documents is Priapism (a prolonged, painful erection). Other psychosexual effects, such as changes in libido, have also been reported in both male and female patients.

Q: Is there any risk of seizures associated with the use of Teva-Trazodone?

Regulatory postmarketing reports indicate that seizures and grand mal convulsions have been identified as possible adverse events associated with the use of Trazodone. While these events are not common, they are a documented risk.

Q: Is it possible for Teva-Trazodone to worsen anxiety or cause agitation in some people?

Official product information states that during the initial period of treatment or after a change in dosage, new or worsened emotional or behavioral problems may be experienced by some patients. These changes can include feelings of agitation, hostility, or anxiety.

Q: Does Teva-Trazodone have an effect on eye health, such as a risk of glaucoma?

The drug is associated with a risk of pupillary dilation (widening of the pupil). This effect carries a documented risk of potentially triggering an angle-closure glaucoma attack in patients with pre-existing, anatomically narrow eye angles.

Q: How long does Teva-Trazodone stay in the body after the last tablet is taken?

The process for the drug to be eliminated from the body is measured by its half-life, which is the time it takes for half the drug to be cleared. Official pharmacokinetic data reports the terminal elimination half-life for Trazodone is typically between 5 to 13 hours.

Q: Is a metallic or unpleasant taste in the mouth a known side effect of Teva-Trazodone?

An unpleasant taste in the mouth is reported in clinical summaries as a less common side effect.

Q: Can Teva-Trazodone cause tingling or numbness in the hands or feet?

Less common side effects reported in clinical summaries include feelings of tingling, numbness, or prickling, which is known medically as paresthesia.

Q: Is a stuffy or congested nose a possible side effect of Teva-Trazodone?

Official clinical trial data has reported that nasal congestion and sinus congestion are possible common side effects of Teva-Trazodone.

Q: What research supports the use of Teva-Trazodone for its primary indication?

Clinical summaries indicate that studies examining Trazodone for its approved use in Major Depressive Disorder (MDD) have reported antidepressant activity in line with that of other established drug classes, including tricyclic antidepressants and SSRIs. This documented evidence forms the basis for its primary indication.

How should Teva-Trazodone be stored and disposed of?

Official Storage and Disposal Requirements

Trazodone hydrochloride tablets must be stored at Controlled Room Temperature, which is defined by regulators as 20 C to 25 C (68 F to 77 F), with temporary temperature excursions permitted up to 30 C (86 F).

Protection and Handling

The medicine must be kept out of the reach and sight of children at all times. To protect the product, it is required to store the tablets in the original packaging, ensuring the container is kept tightly closed.

Disposal Instructions

Unused or expired Trazodone must not be discarded in household waste or disposed of by flushing it into wastewater. The official instruction is to consult a pharmacist regarding the proper method for disposing of the medicine, which is required to help protect the environment.

Teva-Trazodone